REFILE-UPDATE 1-Aradigm's inhaled antibiotic fails late-stage study, shares sink

REFILE-UPDATE 1-Aradigm's inhaled antibiotic fails late-stage study, shares sink


Aradigm Corp said on Thursday its inhaled antibiotic for a rare, incurable disorder affecting the lungs failed in a late-stage study, sending the company's shares down nearly 54 percent in premarket trading. The once-a-day formulation, Pulmaquin, is being tested in patients with non-cystic fibrosis bronchiectasis who have chronic lung infections with the bacteria P. aeruginosa, which leads to the enlargement of the lungs' airways.



from Biotech News